Dexmedetomidine vs. Remifentanil for Sedation During AFI
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a
selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for
ICU and intraoperative sedation as a sedative during awake fiberoptic intubation, as compared
to Remifentanil.
The hypothesis is that Dexmedetomidine will provide at least equal if not better conditions
(sedation and analgesia) required for awake fiberoptic intubation (Ramsay Sedation Scale 3)
with less respiratory and cardiovascular adverse effects, as well as less recall than
Remifentanil.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer